Abemaciclib, a Recent Novel FDA-Approved Small Molecule Inhibiting Cyclin-Dependant Kinase 4/6 for the Treatment of Metastatic Breast Cancer: A Mini-Review

ISSN Print: 2164-3121
ISSN Online: 2164-313X
www.scirp.net/journal/ojmc
E-mail: [email protected]

Citations

"Abemaciclib, a Recent Novel FDA-Approved Small Molecule Inhibiting Cyclin-Dependant Kinase 4/6 for the Treatment of Metastatic Breast Cancer: A Mini-Review"
written by Lou Anna Voli, Janat A. Mamyrbékova, Jean-Pierre Bazureau,
published by Open Journal of Medicinal Chemistry, Vol.10 No.3, 2020

has been cited by the following article(s):

[1]	Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective
	Pharmaceuticals, 2023

[2]	A review of FDA approved drugs and their formulations for the treatment of breast cancer
	Frontiers in Pharmacology, 2023

[3]	Structure-based methods in drug design
	… , QSAR and Machine …, 2023

[4]	Molecular perspective on targeted therapy in breast cancer: a review of current status
	Medical Oncology, 2022

[5]	Introductory chapter: Protein kinases as promising targets for drug design against cancer
	Protein kinases promising targets for …, 2021

[1]	Development of a stability-indicating RP-UPLC method for simultaneous determination of Abemaciclib and Olaparib with LC–MS characterization of degradation products and in vitro performance evaluation Journal of Chromatographic Science, 2026 DOI:10.1093/chromsci/bmag022

[2]	Life as Basic Science: An Overview and Prospects for the Future [Volume 2] 2024 DOI:10.52756/lbsopf.2024.e02.014

[3]	A review of FDA approved drugs and their formulations for the treatment of breast cancer Frontiers in Pharmacology, 2023 DOI:10.3389/fphar.2023.1184472

[4]	Molecular perspective on targeted therapy in breast cancer: a review of current status Medical Oncology, 2022 DOI:10.1007/s12032-022-01749-1

[5]	Protein Kinases - Promising Targets for Anticancer Drug Research Biochemistry, 2021 DOI:10.5772/intechopen.100315